Page 2 - மூலக்கூறு கூட்டாளர்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Copy URL IT is generally acknowledged that with new, more transmissible and potentially lethal variants spreading worldwide, vaccines are also unlikely to be the complete solution to managing the pandemic. Countries urgently need a broader armoury of effective drugs, particularly those that act early in the disease or as prophylaxis. Accordingly, the developing world is now moving towards administering antibody combinations to treat patients with mild to moderate Covid-19, to better manage emerging variants of concern, stop deaths and reduce the burden on overstretched healthcare systems. One type of intervention that has shown promise is monoclonal antibodies (mAbs). Research overseas has shown that mAbs treatment – when given at an early stage to mild-to-moderate patients – can reduce the progression rate to severe Covid-19 requiring hospitalisation, oxygen therapy and even reduce risk of death.

Khairy jamaluddinEli lillyUniversity of oxfordWorld health organizationDrug administrationGlaxosmithkline singaporeVir biotechnologyWellcome trustMolecular partnersInnovation minister khairy jamaluddinகைரி ஜமாலுதீன்எலி லில்லிபல்கலைக்கழகம் ஆஃப் ஆக்ஸ்ஃபர்ட்உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந்வீர் உயிரி தொழில்நுட்பவியல்வெல்கம் நம்பிக்கை